How much funding has Vivacta Biotechnology raised?

Vivacta Biotechnology has raised $50.0M in total funding, most recently a series a round.

Who are Vivacta Biotechnology's investors?

Vivacta Biotechnology's investors include Decheng Capital, OrbiMed, Loyal Valley Capital, Qiming VP, Eisai.

When was Vivacta Biotechnology founded?

Vivacta Biotechnology was founded in 2025.

Where is Vivacta Biotechnology headquartered?

Vivacta Biotechnology is headquartered in Shanghai, United States.

What industry is Vivacta Biotechnology in?

Vivacta Biotechnology operates in Biotech.

How many employees does Vivacta Biotechnology have?

Vivacta Biotechnology has 51-200 employees.

Vivacta Biotechnology

Pioneering in vivo CAR-T cell therapy.

Shanghai, United States · Founded 2025 · $50.0M raised

Biotech

Headquarters: Shanghai
Employees: 51–200
Founded: 2025
Business Model: B2B

Website: vivacta-bio.com
Total Funding: $50.0M
Last Round: $50.0M Series AApr 2026
Rounds: 2

About

Vivacta Biotechnology is a biotech company developing in vivo CAR-T cell therapies using a T-cell-targeting LNP delivery system. Founded in Shanghai in June 2025, the company focuses on treatments for hematologic malignancies and autoimmune diseases, enabling CAR expression directly within patient T cells without traditional cell isolation procedures.

Summary

Vivacta Biotechnology is a Biotech company based in Shanghai, United States, founded in 2025. It has raised $50.0M in total across 2 rounds, most recently a $50.0M Series A round in Apr 2026. Investors include Decheng Capital, OrbiMed and Loyal Valley Capital.